731: Company sponsored indrect comparison concludes the companyâEURs product is better for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage's primary photo
  • The Elective Rotation 731: Company sponsored indrect comparison concludes the companyâEURs product is better for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage
  • Podcast Episode | 4 min
Primary photo for 731: Company sponsored indrect comparison concludes the companyâEURs product is better for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage

The Elective Rotation

731: Company sponsored indrect comparison concludes the companyâEURs product is better for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage
Podcast Episode | 4 min

No summary details listed. Contribute to this page
Status
Edit Released
Updated Jul 18, 2022

Release date
Jul 18, 2022 (United Kingdom)

Contacts

Become a member to see contact information for 731: Company sponsored indrect comparison concludes the companyâEURs product is better for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage.

Cast

+ Add Cast
0 cast members

Contribute to this section by adding a cast member

There was an issue loading this tab.
There was an issue loading this tab.
There was an issue loading this tab.
There was an issue loading this tab.
There was an issue loading this tab.
There was an issue loading this tab.
There was an issue loading this tab.
There was an issue loading this tab.

MOVIEmeter

Members only

Become a member to access additional data

Ratings Breakdown